Navigation Links
Ranbaxy Launches Omeprazole 40 mg Capsules

GURGAON, India and PRINCETON, N.J., July 28 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), Gurgaon, India announced today that under an agreement with AstraZeneca Pharmaceuticals it has launched an authorized generic of Omeprazole 40 mg Capsules in the U.S. healthcare system. Omeprazole 40 mg is indicated for the treatment of acid-related disease, including gastric ulcer and Zollinger-Ellison syndrome. The most common side effects of Prilosec(R) are headache, diarrhea and abdominal pain. Prilosec(R) 40 mg had sales in the U.S. market of $204.2 million (IMS: March 2008 MAT).

"We welcome the opportunity to market an authorized generic of Omeprazole 40 mg capsules that will be commercialized immediately to all classes of trade in the U.S. healthcare system under the Ranbaxy label," said Jim Meehan, Vice President of Sales and Distribution for RPI. "We will offer this product as an affordable and accessible generic formulation to patients requiring this medication."

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.

CONTACTS: Charles M. Caprariello

Vice President, Corporate Communications

Ranbaxy Inc.

(609) 720-5615

Edwige Buteau

RF Binder Partners Inc.

(212) 994-7517

Caroline Mozingo Dickson

RF Binder Partners Inc.

(212) 994-7560

SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation
2. Ranbaxy Gains Tentative Approval to Manufacture and Market Valganciclovir Hydrochloride Tablets
3. Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules
5. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
6. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
7. Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP
8. GeneNews launches worlds first blood test for colorectal cancer screening
9. Norgen Biotek Corp. Launches Four New Kits for the Purification of RNA and DNA from Plants and Fungi
10. Health Market Science Launches Clinical Investigators(TM)
11. SAFC Supply Solutions Launches REACH-Compliant Products and Support
Post Your Comments:
(Date:12/1/2015)... 2015 Cepheid (Nasdaq: CPHD ) today ... Piper Jaffray Healthcare Conference in New York ... reaffirming its outlook for the fourth quarter of 2015 ... discussing longer term business model expectations. John ... continue to be the fastest growing company of the ...
(Date:12/1/2015)... , December 1, 2015 ... of the  "2016 U.K. Virology and Bacteriology ... for 100 Tests, Supplier Shares by Test, ... to their offering.  --> ... "2016 U.K. Virology and Bacteriology Testing Market: ...
(Date:11/30/2015)... ... ... Cells Group announced the opening of a new core patient care hub with the ... The facilities are part of GSCG’s expansion efforts in Latin America. , Both the ... to patients from around the world. , The clinics will be headed by Victor Perez, ...
(Date:11/30/2015)... , Nov. 30, 2015  Culprits beware, ... assistant chemistry professor Jan Halámek, is taking crime ...   --> ...   --> --> ... UAlbany have discovered a straightforward concept for identifying ...
Breaking Biology Technology:
(Date:11/20/2015)... -- NXTD ) ("NXT-ID" or the "Company"), ... commerce market and creator of the Wocket® smart wallet, ... interviewed on The RedChip Money Report television ... Bloomberg Europe , Bloomberg Asia, Bloomberg Australia, and ... ) ("NXT-ID" or the "Company"), a biometric authentication company ...
(Date:11/18/2015)... , November 18, 2015 ... published a new market report titled  Gesture Recognition Market ... Forecast, 2015 - 2021. According to the report, the global gesture ... is anticipated to reach US$29.1 bn by 2021, at ... North America dominated the global ...
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
Breaking Biology News(10 mins):